Lv5
1400 积分 2024-01-11 加入
Abstract 2435: Tertiary lymphoid structures induction predicts and enhances response to famitinib plus PD-L1 blockade in advanced thyroid cancer
23天前
已关闭
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer
1个月前
已完结
Origins and consequences of cognitive fatigue
1个月前
已完结
Why time poverty matters for individuals, organisations and nations
1个月前
已完结
The next generation of immunotherapies for lung cancers
1个月前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
1个月前
已完结
When the real world becomes the trial
1个月前
已完结
Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
2个月前
已完结
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer
2个月前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
